882 results about "Chondroitin" patented technology

A dietary supplement blend composition is disclosed, the basic formulation of the composition containing vitamins, minerals, and carotenoids. The composition can also contain bioflavonoids, cartilage protectors such as glucosamine or chondroitin, alpha-lipoic acid, coenzyme Q10, and a source of omega-3 fatty acids such as flax seed oil. The composition is beneficial for improving health and preventing disease, particularly for degenerative conditions. A method for supplementing the diet is also disclosed, wherein the quantity of daily rations of the dietary supplement blend composition is determined based on the person's age, body weight, and quality of diet.

The present invention relates to a method and transdermal pharmaceutical composition for preventing or reducing the likelihood of calcium deficiency or imbalances caused by calcium deficiency. The transdermal pharmaceutical composition includes a therapeutically effective amount of a pharmaceutically acceptable salt of calcium and a pharmaceutically acceptable carrier constituting a pluronic lecithin organogel. In addition to calcium, the transdermal pharmaceutical composition may also contain a therapeutically effective amount of: (1) a pharmaceutically acceptably salt of other minerals such as magnesium, zinc, selenium, manganese, or chromium; (2) a vitamin such as vitamin A, vitamin D, vitamin C, vitamin E or B-complex vitamins, choline, lecithin, inositol, PABA, biotin, or bioflavomoids; (3) a carotenoid such as lycopene or lutein; (4) a hormone such as dehydroepiandrosterone, progesterone, pregnenolone, or melatonin; (5) an amino acid such as arginine, glutamine, lysine, phenylalanine, tyrosine, GABA, tryptophan, carnitine, or acetyl-l-carnitine; (6) a fatty acid such as a fish oil or flax seed oil; (7) a vita-nutrient such as coenzyme Q10; (8) a cartilage building nutrient such as glucosamine, chondroitin, or MSM, (9) a herb such as ginkgo biloba, echinacea, 5-HTP, St. John's wort, or saw palmetto; or (9) any combination thereof. The transdermal pharmaceutical composition may be topically administered to a human to prevent or reduce the likelihood of calcium deficiency or imbalances caused by calcium deficiency such as hypertension, high cholesterol, colon and rectal cancer, osteomalacia, rickets, osteoporosis, cardiovascular disease, preeclampsia, tooth decay, and premenstrual syndrome.

The present invention relates to compositions of and methods for producing timed or retarded release formulations that contain glucosamine sulfate, beta-(1,4)-2-amino-2-deoxy-D-glucose, and chondroitin, (C₁₄H₁₉NO₁₄SNa₂)_n; N-acetylchondrosanine (2-acetamide-2-deoxi-D-galactopiranose) and D-gluoronic acid copolymer and/or their dietary and nutraceutically acceptable salts of the same and/or hydrates of the active substance that provide a timed release formulation of the active substance.

The invention provides a method of promoting neuronal plasticity in the CNS of a mammal, the method comprising administering to the CNS of the mammal an agent that reduces the inhibitory properties of chondroitin sulphate proteoglycans. Preferred agents are chondroitinases and sulfatases, e.g., chondroitinase ABC. Also provided are methods of identifying further agents.

The invention discloses a method for separating chondroitin polysulfate from heparin sodium by an extraction method, breaking through the conclusion drawn by domestic and international experts, i.e., the chondroitin polysulfate in the heparin sodium is inseparable. The technical scheme is as follows: an acetone extraction method is adopted to remove the chondroitin polysulfate in the heparin sodium and thoroughly separate the chondroitin polysulfate from the heparin sodium by the refinement steps of crude product dissolution, enzymolysis, rapid heating, impurity centrifugation, a plurality of precipitation and oxidation so that the refined product rate of the heparin sodium reaches over 83 percent, the activity valence is over 180 usp/mg and over 200 iu/mg by being converted into the WHO international standard, and the quality standard accords with various indexes specified by Chinese pharmacopoeias, America pharmacopoeias, English pharmacopoeias and Western European pharmacopoeias.

The present invention relates to methodology for polymer grafting by a polysaccharide synthase and, more particularly, polymer grafting using the hyaluronate or chondroitin or heparin/heparosan synthases from Pasteurella, in order to create a variety of glycosaminoglycan oligosaccharides having a natural or chimeric or hybrid sugar structure with a targeted size that are substantially monodisperse in size. The present invention also relates to methodology for polymer grafting by a polysaccharide synthase to form glycosaminoglycan polymers having an unnatural structure.

The invention relates to the discovery of a novel Chondroitinase Glycoproteins (CHASEGP's), methods of manufacture, and potential uses in conditions where removal of chondroitin sulfates may be of therapeutic benefit. Chondroitinase Glycoproteins require both a substantial portion of the catalytic domain of the CHASEGP polypeptide and asparagine-linked glycosylation for optimal chondroitinase activity. The invention also includes carboxy-terminal deletion variants of CHASEGP that result in secreted variants of the protein to facilitate manufacture of a recombinant CHASEGP. Further described are suitable formulations of a substantially purified recombinant CHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity. CHASEGP is useful for the degradation of glycosaminoglycans and chondroitin sulfate proteoglycans under clinical conditions where their removal is of therapeutic value.

The invention relates to health food for enhancing human immunity and increasing bone mineral density and a preparation method thereof; the health food of the invention comprises the following components: hyaluronic acid, glucosamine, collagen, kudzu root extracts, chondroitin sulfate, vitamins, calcium, etc; because of the embedding processing of hyaluronic acid, the defect of property change of hyaluronic acid due to moisture absorption and influence of environmental factors is overcome; the health food prepared by the organic combination of the embedded hyaluronic acid with glucosamine, collagen, plant extracts, vitamins, mineral matter and the like has functions and effects which can supplement each other, has the effects of lubricating joints, increasing bone mineral density, and enhancing bone strength during long-term administration, and also has the functions of delaying aging, removing freckles and beautifying faces, and the like; the health food of the invention can be prepared into powder, granules, tablets, capsules, is convenient for carrying and taking, has stable and lasting efficacy, has no side effects, and is an ideal health food of patients with hypoimmunity and osteoporosis.

A method of preventing or treating pain or inflammation in a subject is provided by administering to the subject a Cox-2 inhibitor and a polyunsaturated fatty acid, or a prodrug thereof, wherein the amount of a Cox-2 inhibitor and polyunsaturated fatty acid or a pharmaceutically acceptable salt or prodrug thereof together constitute a pain or inflammation suppressing treatment or prevention effective amount. Glucosamine and/or chondroitin can optionally be present. Therapeutic compositions that contain the combination of Cox-2 inhibitor and polyunsaturated fatty acid and, optionally, the glucosamine and/or chondroitin, are disclosed, as are pharmaceutical compositions.

The present invention relates to a biological fermentative production technology of extracting high-calcium powder, chondroitin sulfate and collagen from animal cartilage which includes the following steps: the animal cartilage is simply broken into 5-20mm fragments, mixed with 1-4 times weight of water in the reaction kettle, heated to 100DEG C and kept for 1-2 hours to denature the proteins, then cold water is passed over into the kettle jacket to cool down the kettle to 40-50DEG C, compound enzyme in mass ratio of 1:0.001 which is mainly collagenase is then added, the mixture is stirred and hydrolyzed for 8-12 hours under the condition of 40-50DEG C, pH 7-8, bone residue that contains calcium phosphate is obtained after simple filtration through 100-meshed sieves; the filtrate is clarificated after fine filtration with filter press, then ethanol is added to the final concentration of 60-70%, chondroitin will be sedimentated, while remaining liquid is the mixture of collagen and ethanol. The sedimentated calcium phosphate is washed and dried and becomes calcium phosphate powder. The crystal sediment of chondroitin is purified by ethanol-washing. Collagen is separated after the mixture of collagen and ethanol goes through the ethanol regenerating column. This technology can produce different products with high purity from animal cartilage and solves the problems of pollution and single product of traditional technology.

A therapeutic composition and methods for the treatment and prevention of a degenerative joint disorder and/or a cardiovascular disease comprising polycosanols, glucosamine and chondroitin are disclosed.

One aspect of the present invention relates to mutants of chondroitinase ABCI. Such chondroitinase ABCI mutants exhibit altered chondroitin lyase activity or increased resistance to inactivation from stressors including exposure to UV light or heat. Methods of using chondroitinase ABCI mutant enzymes are also provided.

The present invention relates to porous laminated 3D tissue rack material and its preparation process. Polylactic aicd, polyglycolic acid, glycolic acid copolymer, polycaprolactone or other bioabsorbable material and chitosan, chondroitin sulfate, collegen, heparin sulfate, sodium alginate, hyaluronic acid, etc are used as the base material. The preparation process includes nanometer self-assembling to assemble chitosan, chondroitin sulfate or other positively or negatively charged medical polymer material to the surface of specific cylindrical core material, vacuum drying and freeze drying to form the highly bionic human body tubular tissue rack material with adjustable structure, size and shape.

The invention provides a tissue engineering artificial skin and a preparation method thereof. The artificial skin comprises an epidermal layer and a dermal layer, wherein the epidermal layer material is made of collagen or a mixed material of collagen and chitosan; the dermal layer material is made of collagen or a mixed material of collagen and chitosan, hyaluronic acid, chondroitin sulfate, alginate or polyving akohol. The epidermal layer comprises a semipermeable film; the dermal layer comprises two layers of three-dimensional porous supporting structures with different porosities. The used collagen is end-free collagen, so that the problems of immune rejection, foreign body reaction, viral infection and the like of the artificial skin during application are solved. The invention further provides the preparation method for the tissue engineering artificial skin.

The present invention concerns multilayer films comprising a plurality of layers, at least some of the layers comprise (i) cross-linked chitosan, alginate, chondroitin sulfate, or hyaluronic acid and (ii) particles or void spaces; wherein the layers are 20-260 nm in thickness. Also disclosed are multilayer films comprising at least two of: a layer comprising a first polymer; a layer comprising a second polymer; a layer comprising particles, wherein said particles comprise ceramic material, metallic species, or both; and, a layer comprising a combination of said first polymer and said particles; wherein said multilayer film is capable of displaying structural color. Also provided are methods for making and using the inventive multilayer films and compositions comprising the multilayer films.

The invention discloses a preparation method of hyaluronic acid/gelatin/chondroitin sulfate bone repair bionic scaffold. The method comprises the steps of adding activator and furfurylamine into MES buffer solution of hyaluronic acid to obtain modified hyaluronic acid solid; adding EDC/NHS (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide/N-hydroxysuccinimide) into gelatin aqueous solution, and adding furancarboxylic acid to obtain modified gelatin solid; dissolving the above two solids into MES buffer solution to obtain a mixed solution; dissolving MAL-PEG-MAL (maleimide-polyethylene glycol-maleimide) into MES buffer solution, adding into the mixed solution, and reacting in 37 DEG C water bath to form transparent cross-linked hydrogel; soaking the hydrogel in MES buffer solution of sodium chondroitin sulfate, adding EDC/NHS, and reacting under stirring to obtain the cartilage repair bionic scaffold. The bionic scaffold has the advantages of interpenetrating network structure, excellent biocompatibility and bioactivity, better compression strength, anti-washout property and degradability, simple preparation process, and easy operation.

The present invention relates to surgical material. The material includes biologically absorbable polymer 10-90 wt%, un-sintered calcium phosphate salt 5-80 wt%, and bone growth factor less than 10 wt%. The biologically absorbable polymer includes polyester, chitosan, chondroitin sulfate, collagen, alginate, etc.; and the calcium phosphate salt is un-sintered hydroxyapatite or tricalcium phosphate of granularity less than 100 microns. The hard tissue repairing material is prepared through mixing biologically absorbably polymer, un-sintered calcium phosphate salt and bone growth factor dispersed in solvent, molding, freeze drying to eliminate solvent and obtain the composition. The composition has the function of promoting bond healing and excellent biocompatibility.

The invention relates to the field of recombinant DNA technology for the production of chondroitin, including the production of chondroitin sulfate via a combination of recombinant bacterial fermentation and post-fermentation sulfation.

A method for producing a chondroitin sugar chain comprises at least the following step: a step of allowing “a glucuronic acid donor”, “an N-acetyl galactosamine donor”, “a sugar receptor” and “a bacterial cell enzyme which synthesizes chondroitin” to coexist in a reaction system in the presence of a surfactant. Here, the surfactant is preferably selected from n-nonyl-β-D-thiomaltopyranoside, sucrose monocaproate and sucrose monolaurate. The chondroitin sugar chain has all the following properties 1) to 3): 1) a weight average molecular weight: 50,000 or more when it is measured by gel filtration chromatography, 2) it is completely degraded to disaccharides with chondroitinase ABC, 3) when the sugar chain is decomposed with chondroitinase ABC and the decomposed products are subjected to a disaccharide analysis, substantially all of them correspond to an unsaturated disaccharide unit of chondroitin.

The composite bone tissue engineering rack material includes collagen, hydroxyapatite, chondroitin sulfate and bone morphogenetic protein; and has 3D porous structure of aperture 50-150 microns. The ratio between collagen and hydroxyapatite is 1 to 1-10, and the chondroitin sulfate is compounded with other components via cross-linking. The material may be constituted into tissue engineering artificial bone based on tissue engineering principle. The present invention has excellent physical, chemical and biological performance, is excellent bone tissue engineering rack material, and may be used in repairing bone defect caused by different reasons clinically.

Method and composition for a formulation applied to the skin in a transdermal delivery system to address discomfort from various musculoskeletal conditions. The formulation comprises 0.01% to 20% by weight of glucosamine, 0.01% to 20% by weight of chondroitin sulfate, 0.01% to 10% by weight of camphor, 0.01% to 10% by weight of menthol, 0.01% to 20% by weight of an anti-inflammatory agent, and a transdermal component.

A composition comprising an amphoteric or pseudo-amphoteric agent and a polyhydroxy alpha hydroxyacid existing as a free acid, lactone, or salt, and isomeric or non-isomeric forms thereof is provided. The amphoteric or pseudo-amphoteric agent can be selected from amino acids, dipeptides, aminoaldonic acid, aminouronic acid, lauryl aminoproplyglycine, aminoaldaric acid, neuraminic acid desulfated heparin, deacetylated hyaluronic acid, hyalobiuronic acid, chondrosine, deacetylated chondroitin, creatine, creatinine, hydroxyproline, homocysteine, homocystine, homoserine, ornithine, citrulline, phosphatidylserine, and sphingomyelin. The composition may contain other additives, including cosmetic or pharmaceutical agents for topical treatment of dermatological disorders.